肿瘤细胞治疗研究
英文原题：Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity after Supportive Stem Cell Boost in Multiple Myeloma.
双特异性抗体显著扩展了多发性骨髓瘤的治疗手段。
引言：双特异性抗体显著扩展了多发性骨髓瘤的治疗手段。Talquetamab是一种靶向GPRC5D、可重定向CD3+ T细胞的抗体；GPRC5D表达于多发性骨髓瘤浆细胞及角化组织。鉴于其表达分布，talquetamab可导致皮肤毒性。 病例报告：我们报告一名患者在CAR-T治疗后复发，随后接受talquetamab治疗。该患者接受造血干细胞支持性回输以治疗CAR-T后持续的晚期血细胞减少后，talquetamab介导的皮肤毒性严重复发。 结论：该病例凸显多发性骨髓瘤治疗中talquetamab等新型免疫疗法与干细胞干预之间的复杂相互作用，提示需要个体化方案，在最大化疗效的同时降低相关不良反应。
INTRODUCTION: Bispecific antibodies have meaningfully expanded the therapeutic armamentarium in multiple myeloma. Talquetamab is a CD3+ T-cell-redirecting antibody targeting GPRC5D, which is expressed on multiple myeloma plasma cells as well as in keratinized tissues. Due to the expression pattern, toxicity of talquetamab involves skin toxicity. CASE PRESENTATION: Here we report the case of a patient who was treated with talquetamab after relapse after CAR-T therapy. The patient developed a severe recurrence of talquetamab-mediated skin toxicity after the administration of a supportive hematopoietic stem cell boost to treat persistent late cytopenias after CAR-T therapy. CONCLUSION: This case underscores the complex dynamics between novel immunotherapies like talquetamab and stem cell-based interventions in the context of MM treatment, shedding light on the need for personalized approaches to maximize the benefits of these therapies while minimizing their associated adverse effects.
MEMBER ACCOUNT
登录成功会直接打开下一页。
